New immunotherapy cocktail shows promise for tough lung cancer

NCT ID NCT05420220

Completed Disease control Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 study tested a combination of two drugs—KN046 (an immunotherapy) and axitinib (a targeted therapy)—in 95 people with advanced non-small cell lung cancer that had not been treated before. The goal was to see if the combo could shrink tumors and how safe it was. The trial is now complete, and results will help decide if further testing is warranted.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: KN046 (an experimental immunotherapy) combined with axitinib (a targeted cancer pill)
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced lung cancer that has not responded to other therapies.
What could go wrong: This is an early-phase trial with only 95 participants, so results may not apply to everyone. Side effects from the drug combination could be serious, and the treatment may not work for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Linyi Cancer Hospital

Linyi, Shandong, China
Shanghai Chest Hospital

Shanghai, Shanghai Municipality, China
Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China
The Second Hospital of Anhui Medical University

Hefei, Anhui, China
The first affiliated hospital, Zhejiang university

Hangzhou, Zhejiang, China
Yantai Yuhuangding Hospital

Yantai, Shandong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.